Loading data for SDZXF — first visit, this takes a few seconds.
Sandoz Group AG
81.33 -7.93 (-8.88%)
- Capitalización de mercado
- $34.79B
- Volumen
- 100
- Próxima fecha de resultados
- Feb 17, 2027
Sandoz Group AG (SDZXF): cotización, análisis y datos
Valor intrínseco
Pronóstico del analista
Previsiones bursátiles →Últimos resultados
| Reportado | Vs. estimación | Cambio interanual | |
|---|---|---|---|
| Ingresos | — | n/a | n/a |
| EPS | — | n/a | n/a |
Métricas
- Precio de compra
- 79.9
- Ingresos (TTM)
- 11.7B
- Beneficio neto (TTM)
- 646M
- 0.49
- 1.47
- 54.69
- n/a
- P/B (TTM)
- 3.89
- P/S (TTM)
- 2.98
- Fecha de resultados
- Feb 17, 2027
- Precio de venta
- 84.29
- Volumen
- 100
- Volumen medio (20D)
- 522
- Abierto
- 81.25
- Anterior Cerrar
- 89.26
- Rango del día
- 81.25 - 81.25
- Rango de 52 semanas
- 55.50 - 94.55
- analista
- n/a
- Precio objetivo
- n/a
- Dividendos
- $1.02 (1.27%)
- Fecha ex dividendo
- Apr 13, 2026
Acerca de Sandoz Group AG
Ver perfil →Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company has a strategic collaboration with Shanghai Henlius Biotech, Inc. to broaden patient access to biosimilar medicines. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland.
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company has a strategic collaboration with Shanghai Henlius Biotech, Inc. to broaden patient access to biosimilar medicines. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland.
Industria Drug Manufacturers - Specialty & Generic
Sector Healthcare
IPO Fecha Oct 9, 2023
Empleados 20,000
Bolsa de Valores OTC Markets OTCQX
Símbolo bursátil SDZXF
Sitio web https://www.sandoz.com